AU2002228913A1 - Use of inhibitors of lyn-associated signal transduction (last) in the treatment of prostate cancer - Google Patents
Use of inhibitors of lyn-associated signal transduction (last) in the treatment of prostate cancerInfo
- Publication number
- AU2002228913A1 AU2002228913A1 AU2002228913A AU2891302A AU2002228913A1 AU 2002228913 A1 AU2002228913 A1 AU 2002228913A1 AU 2002228913 A AU2002228913 A AU 2002228913A AU 2891302 A AU2891302 A AU 2891302A AU 2002228913 A1 AU2002228913 A1 AU 2002228913A1
- Authority
- AU
- Australia
- Prior art keywords
- lyn
- inhibitors
- treatment
- prostate cancer
- signal transduction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/735,279 US20020019346A1 (en) | 1997-05-21 | 2000-12-11 | Treatment of prostate cancer by inhibiting lyn tyrosine kinase |
US09/735,279 | 2000-12-11 | ||
PCT/US2001/047444 WO2002047710A2 (en) | 2000-12-11 | 2001-12-11 | Use of inhibitors of lyn-associated signal transduction (last) in the treatment of prostate cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2002228913A1 true AU2002228913A1 (en) | 2002-06-24 |
Family
ID=24955113
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002228913A Abandoned AU2002228913A1 (en) | 2000-12-11 | 2001-12-11 | Use of inhibitors of lyn-associated signal transduction (last) in the treatment of prostate cancer |
Country Status (6)
Country | Link |
---|---|
US (3) | US20020019346A1 (de) |
EP (1) | EP1366063B1 (de) |
AT (1) | ATE423129T1 (de) |
AU (1) | AU2002228913A1 (de) |
DE (1) | DE60137721D1 (de) |
WO (1) | WO2002047710A2 (de) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2458452C (en) * | 2001-08-10 | 2011-04-19 | Takeda Chemical Industries, Ltd. | Gnrh agonist combination drugs |
WO2003102027A1 (en) * | 2002-05-31 | 2003-12-11 | Serono Genetics Institute S.A. | Homotrimeric extended obg3 globular head and uses thereof |
US20070010468A1 (en) * | 2003-04-23 | 2007-01-11 | Georgetown University | Methods and compositions for the inhibition of stat5 in prostate cancer cells |
CA2620065C (en) | 2005-08-22 | 2011-03-29 | Melior Discovery, Inc. | Methods and formulations for modulating lyn kinase activity and treating related disorders |
MX2009008874A (es) * | 2007-02-20 | 2009-10-20 | Melior Pharmaceuticals I Inc | Metodos para identificar activadores de cinasa lyn. |
WO2009015133A1 (en) * | 2007-07-23 | 2009-01-29 | Melior Discovery, Inc. | Methods of activating irs-1 and akt |
US8552184B2 (en) * | 2008-07-03 | 2013-10-08 | Melior Pharmaceuticals I, Inc. | Compounds and methods for treating disorders related to glucose metabolism |
WO2011150300A1 (en) | 2010-05-28 | 2011-12-01 | Melior Pharmaceuticals I, Inc. | Prevention of pancreatic beta cell degeneration |
SG11201909406VA (en) | 2017-04-10 | 2019-11-28 | Melior Pharmaceuticals I Inc | Treatment of adipocytes |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07507995A (ja) * | 1992-03-02 | 1995-09-07 | バイオジェン,インコーポレイテッド | トロンビンレセプターアンタゴニスト |
US5508383A (en) * | 1994-03-09 | 1996-04-16 | Tap Holdings Inc. | Cyclic peptide LHRH antagonists |
US6723694B1 (en) * | 1997-05-21 | 2004-04-20 | The Children's Medical Center Corp. | Short peptides which selectively modulate intracellular signalling |
WO1999045009A1 (en) * | 1998-03-04 | 1999-09-10 | Bristol-Myers Squibb Company | Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors |
-
2000
- 2000-12-11 US US09/735,279 patent/US20020019346A1/en not_active Abandoned
-
2001
- 2001-12-11 WO PCT/US2001/047444 patent/WO2002047710A2/en not_active Application Discontinuation
- 2001-12-11 AT AT01990038T patent/ATE423129T1/de not_active IP Right Cessation
- 2001-12-11 US US10/012,030 patent/US20020151497A1/en not_active Abandoned
- 2001-12-11 DE DE60137721T patent/DE60137721D1/de not_active Expired - Fee Related
- 2001-12-11 EP EP01990038A patent/EP1366063B1/de not_active Expired - Lifetime
- 2001-12-11 AU AU2002228913A patent/AU2002228913A1/en not_active Abandoned
-
2006
- 2006-12-21 US US11/614,157 patent/US20080045460A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20020019346A1 (en) | 2002-02-14 |
EP1366063B1 (de) | 2009-02-18 |
US20020151497A1 (en) | 2002-10-17 |
EP1366063A2 (de) | 2003-12-03 |
WO2002047710A3 (en) | 2003-04-24 |
ATE423129T1 (de) | 2009-03-15 |
WO2002047710A2 (en) | 2002-06-20 |
US20080045460A1 (en) | 2008-02-21 |
DE60137721D1 (de) | 2009-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003073999A3 (en) | Pini-modulating compounds and methods of use thereof | |
MY134783A (en) | Rho-kinase inhibitors | |
WO2003074550A3 (en) | Pin1-modulating compounds and methods of use thereof | |
IL173348A0 (en) | Thienopyridine and furopyridine kinase inhibitors | |
IL175770A0 (en) | Novel use of peptide compounds for treating central neuropathic pain | |
YU17402A (sh) | Nova spiroheterociklična jedinjenja upotrebljiva kao reverzibilni inhibitori cisteinskih proteaza | |
MXPA06010904A (es) | Inhibidores de pirazol cinasa triciclicos. | |
AU2001260880A1 (en) | Pharmaceutical compounds for treating copd | |
WO2005007123A3 (en) | Pin1-modulating compounds and methods of use thereof | |
AU2002228913A1 (en) | Use of inhibitors of lyn-associated signal transduction (last) in the treatment of prostate cancer | |
HK1071697A1 (en) | Inhibition of the growth factor dependency of tumor cells | |
WO2004024082A3 (en) | Highly specific modulators of gtpases for target validation | |
YU30003A (sh) | Inhibicija zavisnosti faktora rasta na ćelije tumora | |
MXPA03008946A (es) | Metodos para sintetizar compuestos que contienen fenol. | |
CY1111289T1 (el) | Συνθεσεις αναστολεων ογκου που περιεχουν νιτροακριδινη | |
WO2005056043A3 (en) | Use of enzymatic inhibitors of h-prune for the prevention and treatment of the metastases of tumours overexpressing h-prune | |
LT2003075A (en) | Inhibitor of monoamine uptake | |
IL189502A0 (en) | Methods and compositions for inhibiting neoplastic cell growth | |
AU2576901A (en) | Agents and methods for the treatment of proliferative diseases | |
AU2003236701A1 (en) | Guanidino phenylalanin compounds used as urokinase inhibitors | |
AU2003264707A1 (en) | Use of a chrysanthellum extract | |
MXPA04004757A (es) | Uso de una ascomicina para el tratamiento de blefaritis. | |
WO2002047711A3 (en) | Modulators of activity of g-protein-coupled receptor kinases | |
AU2003282035A1 (en) | Modulation of s6 kinase activity for the treatment of obestiy | |
WO2003004631A3 (en) | USE OF INHIBITORS OF EXPRESSION OR ACTIVITY OF p8/com1 FOR TREATING TUMORS. |